CL2008001216A1 -
Compounds derived from pyrazol-3-yl-amino-pyrimidine; Preparation process; pharmaceutical composition; and use in the treatment of cancer.
- Google Patents
Compounds derived from pyrazol-3-yl-amino-pyrimidine; Preparation process; pharmaceutical composition; and use in the treatment of cancer.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AgfiledCriticalAstrazeneca Ag
Publication of CL2008001216A1publicationCriticalpatent/CL2008001216A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Compuestos derivados de pirazol-3-il-amino-pirimidina; proceso de preparación; composición farmacéutica; y uso en el tratamiento del cáncer.Compounds derived from pyrazol-3-yl-amino-pyrimidine; Preparation process; pharmaceutical composition; and use in the treatment of cancer.
CL2008001216A2008-04-272008-04-25
Compounds derived from pyrazol-3-yl-amino-pyrimidine; Preparation process; pharmaceutical composition; and use in the treatment of cancer.
CL2008001216A1
(en)
Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
COMPOUNDS DERIVED FROM REPLACED HETEROPENTACICLOS; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
Compounds derived from thiazolidinediones and substituted oxazolidinediones; pharmaceutical composition; process of preparation of the pharmaceutical composition; and use in the treatment of diseases such as rheumatoid arthritis, epoc, cancer, among others.
Compounds derived from substituted fused heterocycles, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition; and use in the treatment of cancer.
Compounds derived from 2,7-naphthyridines-1-one, mediators of syk; pharmaceutical composition; and use in the treatment of inflammatory, respiratory, cellular proliferative or autoimmune disease.
Fused heterocyclic compounds derived from pyrimidinones, potent inhibitors of cdc7; pharmaceutical composition; and its use in the prevention or treatment of cancer.
Compounds derived from substituted carboxyamide heterocycles, ar antagonist; pharmaceutical composition comprising them; and use in the treatment of prostate cancer.
COMPOUNDS DERIVED FROM QUINAZOLINA SUBSTITUTES, INHIBITORS OF QUINASA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, ATEROSCLEROSIS AND ARTHRITIS.
Substituted triazine-derived compounds, mediated by inhibition of p13 and mtor kinase; pharmaceutical composition; preparation procedure; and its use in the treatment of different types of cancer.
Compounds derived from imidazo [1,2-a] pyridine; preparation procedure; pharmaceutical composition; intermediate compounds; and use in the treatment of cancer.